Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 2, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 2, 2026
DirectorIndirect holdingOption exercise
Context
Classification
option exercise
Code C — exercise or conversion of a derivative security
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001982614-26-000004
Filed / recorded
Nov 2, 2026, 9:06 PM UTC
Added to OQRO
Nov 3, 2026, 7:43 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Bambusa Therapeutics, Inc.
Issuer CIK
2044950
Ticker
BBTX
Reporting person
Helmut Wolfgang Jeggle
Relationship
Director, 10% owner
Security
Series Seed Plus Preferred Stock
Table
Derivative (Table II)
Transaction date
Nov 2, 2026
Transaction code
C
Shares / units
3,135,066
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Indirect — See footnote
Amendment
No
Footnotes from the filing
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
Shares held by Salvia Investment GmbH ("Salvia"). The Reporting Person is the Managing Director of Salvia GmbH and has sole voting and dispositive power with respect to the shares held by Salvia. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
A Bambusa Therapeutics director paid $2.7M out of pocket for Bambusa Therapeutics shares. 2 other people at Bambusa Therapeutics bought some too, in the same month.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.